QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=3C0722236A41C6A3133E61589B69E909;jsessionid=53792359AD60CFBAC92BD58A19D86323;jsessionid=237524FD48887F368327E283DA5F818A;jsessionid=8F81A6F3D153A5292DBC106621272BD8;jsessionid=2531434D49ED9EAFC601CA4880AA421E;jsessionid=09BC8C25BC68501660B5BB6A81A61F24 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=3C0722236A41C6A3133E61589B69E909;jsessionid=53792359AD60CFBAC92BD58A19D86323;jsessionid=237524FD48887F368327E283DA5F818A;jsessionid=8F81A6F3D153A5292DBC106621272BD8;jsessionid=2531434D49ED9EAFC601CA4880AA421E;jsessionid=09BC8C25BC68501660B5BB6A81A61F24